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Summary
Q fever is caused by the bacterium Coxiella burnetii and has both acute and chronic forms. The 
acute disease is a febrile illness often with headache and myalgia that can be self-limiting whereas 
the chronic disease typically presents as endocarditis and can be life threatening. The normal 
therapy for the acute disease is a two week course of doxycycline, whereas chronic disease 
requires 18-24 months of doxycycline in combination with hydroxychloroquine. Alternative 
treatments are used for pregnant women, young children, and those who cannot tolerate 
doxycycline. Doxycycline resistance is rare but has been reported. Co-trimoxazole is a currently 
recommended alternative treatment, but quinolones, rifampin, and newer macrolides may also 
provide some benefit.
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Q fever diagnosis and treatment
Q fever is a zoonotic disease caused by infection with the intracellular bacterium Coxiella 
burnetii. This gram-negative bacterium has a nearly worldwide distribution and infects a 
wide variety of animals, including mammals, birds, reptiles, and arthropods [1]. The most 
common reservoir species leading to human exposure are thought to be domesticated 
livestock, specifically goats, sheep, and cattle. Livestock animals do not commonly suffer 
from acute disease when infected, but C. burnetii can replicate to high density in the 
placenta and lead to reproductive failure in these animals [2]. When C. burnetii is introduced 
into previously naïve sheep flocks and goat herds, “abortion storms” can occur and these are 
often the first indication of the presence of C. burnetii in the animals. During birth, large 
numbers of C. burnetii can be released into the environment and this often leads to human 
infections [3].
C. burnetii is transmitted to humans by inhalation of aerosols that contain the bacteria. 
These aerosols are often derived from dried animal waste products or birthing fluids. 
Inhalation is thought to result in infection of monocytic cells in the lung [4]. C. burnetii is 
taken up through the endocytic pathway and remains in an acidic vacuole where it replicates 
Financial disclosure
No writing assistance was utilized in the production of this manuscript.
HHS Public Access
Author manuscript
Expert Rev Anti Infect Ther. Author manuscript; available in PMC 2015 October 16.
Published in final edited form as:













slowly [5]. Over time, large numbers of C. burnetii can grow in infected vacuoles, and cell 
egress can release infectious bacteria for further rounds of infection. Humans will typically 
show symptoms 7-21 days after initial infection, with higher doses having shorter incubation 
times [6]. It has been estimated that >50% of human infections could be asymptomatic, with 
concomitant seroconversion [7].
Symptomatic infections can present in both an acute and a chronic form. Acute Q fever is a 
febrile illness that is often accompanied by fatigue, headache, and myalgia [8]. The disease 
can resolve without treatment and the median duration of fever in untreated patients is 9-14 
days [6,9]. More serious presentations that can occur with acute Q fever are pneumonia and 
hepatitis [10]. It is fatal in rare cases. Q fever can also present in a chronic form that can take 
place months or years after the initial infection. Patients with chronic Q fever may or may 
not recall an episode of symptomatic acute Q fever. Chronic Q fever requires growth of C. 
burnetii in an opportune location in the body. The most common presentation for chronic Q 
fever is culture negative infectious endocarditis, but vascular infections in chronic Q fever 
can also be a common manifestation, with fatal aortic aneurysms possible [11,12]. The 
presence of a pre-existing valvulopathy is the most common risk factor associated with 
chronic Q fever endocarditis [13,14].
Because of the ability of C. burnetii to replicate to high density in the placenta, there are a 
special set of risks associated with Q fever during pregnancy. Premature birth, stillbirth, 
intrauterine growth retardation, and low birth weight have all been described as adverse 
pregnancy outcomes due to Q fever [15-18]. Infection during pregnancy can result in a 
chronic infection where the bacteria are not cleared and persist in the placenta throughout 
the pregnancy. The bacteria may also remain after the pregnancy is completed, and could 
renew replication in subsequent pregnancies [19]. Delivery of babies from C. burnetii 
infected mothers can also create a risk for health care workers, as the generation of C. 
burnetii-containing aerosols is possible [20].
Diagnostic strategies
Diagnosis of acute Q fever relies on a combination of PCR and serology. In the first 1-2 
weeks after symptom onset, antibodies against C. burnetii will not be present, but C. 
burnetii DNA can be detected in blood and serum using PCR [21]. A positive PCR result 
will confirm the diagnosis, but negative PCR is inconclusive. For diagnosis by serology, 
serum should be collected during the acute phase of the disease and a convalescent sample 
taken 3-4 weeks later. C. burnetii exists in two distinct phases and phase-specific antibodies 
can be informative. Phase 1 C. burnetii is the virulent form, whereas Phase 2 C. burnetii 
emerges after long-term culture and has low virulence in animal infections [22]. For 
unknown reasons, antibodies against Phase 2 C. burnetii are the first to arise in human 
infections. A four-fold increase in titer of IgG antibodies against Phase 2 C. burnetii 
between acute and convalescent samples will confirm the diagnosis of acute Q fever [23]. 
The indirect fluorescent antibody test (IFA) is used to measure antibody titers. A negative 
titer on the acute sample does not rule out acute Q fever as the sample may have been taken 
prior to the appearance of antibodies. IgG antibody titers against Phase 1 C. burnetii are 
typically lower than anti-Phase 2 IgG titers in acute Q fever [24].
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Diagnosis of chronic Q fever can be made by the detection of C. burnetii in blood or tissue 
by PCR in the absence of an acute infection. However, many patients are PCR negative and 
serology is critical for most diagnoses. In chronic Q fever, Phase 1 antibody titers will 
become elevated and an IgG titer ≥1:1024 against Phase 1 C. burnetii is evidence of chronic 
Q fever. High Phase 1 titer along with the presence of definite endocarditis according to the 
modified Duke criteria, or an identifiable infection at another location, is considered 
confirmation of chronic Q fever [23,25]. It has been suggested that high Phase 1 titers in the 
absence of a confirmed location of infection, but with other clinical signs should be 
considered probable chronic Q fever [25].
Current treatments
Treatment with antimicrobial agents is recommended for both acute and chronic Q fever 
[23]. For acute Q fever, a variety of treatments have been used, but doxycycline is 
considered the reference treatment. Doxycycline has been shown to result in a mean time to 
defervescence of 2-3 days after the start of treatment [26,27], whereas untreated patients 
resolve the fever after a mean of 12.5 days [9]. The β-lactams have very little effect on C. 
burnetii [9,26], but some success has been reported with macrolides, co-trimoxazole, 
quinolones, and rifampin (see below), but none of these are as effective as doxycycline. 
Recent guidelines for treatment and management of Q fever from the US Centers for 
Disease Control and Q fever working group recommend a primary treatment for acute Q 
fever in adults of 100 mg doxycycline twice a day for two weeks [23].
Treatment of chronic Q fever has historically been much more difficult. Doxycycline has 
been the most effective, but relapses after extended treatment were common in the 1980’s 
and 1990’s [28]. Combinations of doxycycline and other classes of antibiotics have been 
tried with a variety of results, but even after extended treatments (3 years) the reappearance 
of C. burnetii and increasing antibody titers were observed [29]. The possibility was 
considered that relapses were so common because C. burnetii replicates in host cell 
phagolysomoes that have pH of around 4.5. The low pH in the intracellular compartments 
could reduce the efficacy of the drugs and prevent bactericidal activity [30,31]. It was 
demonstrated using in vitro experiments that the combination of doxycycline and 
chloroquine had much more bactericidal activity than doxycycline alone [32]. Chloroquine 
is a lysosomotropic agent that increases the pH of the phagolysome. These findings led to 
the combination of hydroxychloroquine and doxycycline as a primary treatment for chronic 
Q fever [33]. The hydroxyl derivative of chloroquine will also raise the pH of lysosomal 
compartments and allow doxycycline to have bactericidal activity against C. burnetii. The 
combination of doxycycline and hydroxychloroquine has been shown to be effective at 
reducing poor outcomes of Q fever endocarditis patients [28,33].
Current recommendations for treatment of chronic Q fever are 100 mg doxycycline twice 
per day combined with hydroxychloroquine three times per day at 200 mg per dose for at 
least 18 months [23,33]. Two daily 100 mg doses of doxycycline have been shown to result 
in serum concentrations of 2-5 mg/L [34,35]. There is evidence that doses resulting in serum 
concentrations higher than 5 mg/L can lead to faster decline in anti-C. burnetii antibodies 
[36], but controlled studies evaluating doxycycline dosage have not been reported.
Kersh Page 3













The usage of doxycycline plus hydroxychloroquine has reduced the time of treatment in 
chronic Q fever patients to 18 months for those with native heart valves and 24 months for 
patients with prosthetic valves. Although still a very long treatment period for a bacterial 
disease, the use of hydroxychloroquine has reduced treatment times that were previously as 
long as five years [29]. Long-term treatment with doxycycline and hydroxychloroquine are 
not without potential complications. Both of these drugs can cause photosensitivity [37], and 
long term use of hydroxychloroquine can lead to retinopathy [38]. A baseline ophthalmic 
evaluation is recommended for patients beginning long term hydroxychloroquine with 
follow-up examinations every six months while on therapy [23,38]. Allergic reactions to 
both drugs have been reported [28].
Although the incidence of Q fever increases with age and most cases are in adults, children 
can be infected with C. burnetii and have symptomatic Q fever [39]. Treatment for children 
with acute Q fever is recommended and current treatment guidelines for children over 8 
years old call for a two week treatment of doxycycline at a dose of 2.2 mg/kg twice per day 
(not to exceed 100 mg per dose) [23]. For children under 8 years old, treatment with 
doxycycline raises additional questions because of the perceived risk of dental staining. 
Therefore for children under 8, a mixture of trimethoprim and sulfamethoxazole at a 1:5 
ratio (co-trimoxazole) is recommended by the CDC [23]. A dose range for the trimethoprim 
component of 4-20 mg/kg (800 mg maximum per dose) is recommended.
Pregnancy
Pregnancy represents a challenge for Q fever treatment. C. burnetii infection of ruminants 
can result in premature birth, weak offspring, or stillbirth [40]. In humans, Q fever during 
pregnancy has been associated with spontaneous abortions, intrauterine growth retardation, 
and intrauterine fetal death [15-18]. Many women develop a serologic profile of chronic Q 
fever during pregnancy, and viable bacteria can be isolated from patients at the end of 
pregnancy, even after treatment [19]. However, studies from Germany and the Netherlands 
have suggested that Q fever during pregnancy does not create increased risk for fetal 
complications, and emphasize the need to balance the risk of treatment with the potential for 
poor fetal outcome [41,42]. The current recommendation from the CDC is to treat women 
with acute Q fever with co-trimoxazole up until the final six weeks of pregnancy, and to 
give doxycycline and hydroxychloroquine postpartum for 12 months to women that develop 
a serologic profile of chronic Q fever (Phase 1 IgG titer ≥1:1024) [23]. Doxycycline is 
contraindicated during pregnancy because of risk to the fetus. The US Food and Drug 
Administration places doxycycline in pregnancy category D, indicating there is positive 
evidence of risk to the fetus if doxycycline is taken during pregnancy. Co-trimoxazole has a 
category C rating, indicating that adverse effects have been observed in animal studies, but 
adequate studies in humans have not been reported.
Need for alternative therapies
Although doxycycline is effective for Q fever treatment, there are reasons to seek alternative 
therapies. Coxiella burnetii is considered a category B agent of bioterrorism by the CDC. It 
is possible to produce large quantities of organisms and these would be quite stable in 
storage and transport. The organisms are highly infectious and transmitted by inhalation. 
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Dispersal of concentrated aerosols over a large area would be expected to infect large 
numbers of people [43]. For these reasons, the US biological weapons program tested C. 
burnetii on human subjects in the 1950’s and 1960’s as part of “Project Whitecoat” [6,44]. 
In these studies, C. burnetii was found to be able to infect humans at a very low dose of less 
than 10 organisms, and aerosol dispersal was effective for human infection [6]. Although 
use of C. burnetii as a weapon would not be expected to cause widespread fatalities, it is 
thought that significant impairment of physical activity could be achieved, along with 
associated alarm in the population and significant long-term morbidity for a subset of 
victims [43]. Recent advances in microbiological techniques make it conceivable that C. 
burnetii could be modified for greater virulence or made to have antibiotic resistance [45].
In addition to the potential of engineered antibiotic resistance in C. burnetii, natural 
resistance to doxycycline is also a concern. Although resistance to doxycycline does not 
appear to be a common occurrence, doxycycline resistant isolates do exist. In 2005, 3 
isolates with doxycycline minimum inhibitory concentrations (MICs) of greater than 8 μg/ml 
were reported [46]. This included one from an endocarditis patient that died during 
treatment with doxycycline, one isolate from a goat, and a third from a human acute Q fever 
case. The genome sequence from the resistant isolate obtained from the endocarditis patient 
is available [47], but no potential mechanisms of resistance have been described. The extent 
of doxycycline resistance is not known. It can be difficult to obtain human isolates and 
testing for doxycycline resistance is not commonly performed. However, advent of newer 
assays based on real-time PCR have allowed more testing of new isolates in recent years 
[48].
Pregnancy also presents a need for more alternative therapies for Q fever. The reference 
treatment of doxycycline is not acceptable for use in pregnancy due to risk to the fetus, and 
negative effects of co-trimoxazole have not been ruled out [23,49]. Not all studies of Q fever 
during pregnancy have found a large impact on fetal health, suggesting that strain and host 
factors may influence whether acute Q fever can impair fetal growth and development 
[41,42,50]. This raises questions about the universal need for treatment during pregnancy, 
and the risk/benefit calculation that must be made. Safer alternative therapies would be 
beneficial.
The current protocol of using doxycycline plus hydroxychloroquine to treat chronic Q fever 
represents a significant improvement over previous therapies. Examination of Q fever 
endocarditis outcomes in France from 1983 to 2006 shows that use of the combination 
therapy has coincided with reduced mortality and a reduced need for heart valve 
replacement [28]. However, relapses can still occur and the treatment recommendation of 
antimicrobial therapy for at least 18 months is one of the longest treatment regimens used 
for a bacterial infection. Alternative or adjuvant therapies would be beneficial for Q fever 
endocarditis with the goal of shortening the duration of therapy and reducing relapse events.
Alternatives for Q fever treatment
A number of different antibiotic therapies have been investigated for Q fever (Table 1). 
Some have been given intentionally for Q fever treatment, or given as an empiric treatment 
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before a diagnosis was made, or investigated for efficacy against C. burnetii in vitro. 
Randomized, controlled studies evaluating different treatments have not been reported for 
acute or chronic Q fever. Current treatment recommendations are based on combinations of 
case studies, retrospective cohort studies, and in vitro data. Many of the in vitro studies were 
performed by counting the number of visually infected cells under the microscope [51,52], 
but more recent studies have evaluated growth using real-time PCR [48]. The quinolones 
have been used with some success [51]. In vitro, gatifloxacin has been shown to be highly 
effective, and moxifloxacin, gemifloxacin, levofloxacin, pefloxacin, and ofloxacin also have 
some inhibition of C. burnetii growth [52-56]. Ciprofloxacin has some antimicrobial effect, 
but not as strong as the other quinolones [52,54]. A more recent study using real-time PCR 
to get a better quantitative assessment of C. burnetii growth found very little effect for 
ciprofloxacin [48]. The β-lactam antibiotics, including penicillin, amoxicillin, and 
cephalosporins, appear to have little effect on the growth of C. burnetii [9,26,48,57].
In vivo use of quinolones has primarily been associated with Q fever endocarditis. 
Combinations of quinolones and doxycycline were mainly used before 1999 [28]. The drugs 
ofloxacin and pefloxacin showed some benefit for chronic Q fever when used in conjunction 
with doxycycline, but success was limited and required at least three years of treatment [29]. 
In 1999 a study was published that compared the combination of doxycycline and 
hydroxychloroquine to the combination of doxycycline and ofloxacin [33]. It was thought 
that this combination would be more effective due to the ability of hydroxychloroquine to 
raise the pH of the phagolysosomes where C. burnetii replicates and allow more effective 
doxycycline activity [32]. Indeed, the doxycycline/hydroxychloroquine combination allowed 
a reduced duration of treatment and had fewer relapses [33]. Although before 1999 
doxycycline in combination with quinolones was considered a reference treatment, this 
combination has not been widely used since that time [28].
Rifampin has been used with some success against C. burnetii. In vitro studies have found it 
to be very effective [48,57]. Rifampin is usually used in combination with other drugs 
because the risk of developing drug resistance is high. Before the common usage of 
hydroxychloroquine, a combination of rifampin plus doxycycline was sometimes used for 
the treatment of Q fever endocarditis [28,29]. Rifampin has also been used to treat Q fever 
during pregnancy [58,59]. A combination of rifampin and erythromycin has resulted in a 
successful delivery and recovery from a human placental infection [58]. Rifampin is placed 
in pregnancy category C by the US FDA.
Macrolides can have an effect on C. burnetii growth but the results of their use has been 
somewhat mixed. Some in vitro studies have found very little inhibition of C. burnetii 
growth in the presence of erythromycin or azithromycin [46,52]. However, in 13 C. burnetii 
isolates that were resistant to erythromycin in vitro, growth inhibition was observed in the 
presence of telithromycin [46]. Other studies have found inhibition of C. burnetii growth by 
clarithromycin in vitro, although it was generally not as effective as doxycycline or some 
quinolones [53,54,60]. Inhibition of growth at a low MIC using azithromycin in vitro has 
also been reported [60].
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In spite of these mixed results using macrolides in vitro, studies of Q fever patients treated 
with macrolides suggest that these drugs can have some benefit. Acute Q fever pneumonia 
patients given treatment with macrolides have been reported. A study of 11 acute Q fever 
patients from Spain that were given erythromycin found that all 11 had rapid improvement 
and were afebrile by the fourth day of treatment [61]. Only 2 of 8 patients on other 
antibiotics improved during this time frame. Patients not responding to other antibiotics 
promptly improved after beginning erythromycin treatment [61]. A second study from Spain 
found that 25 acute Q fever pneumonia patients improved rapidly after treatment with 
erythromycin, although not as quickly as 23 patients receiving doxycycline treatment [27]. 
A larger study of 113 Greek acute Q fever patients found that erythromycin, clarithromycin, 
and roxithromycin were all effective at reducing the duration of fever [26]. Although not as 
effective as doxycycline, the macrolides were much more effective than β-lactams. 
Macrolides are an attractive potential alternative therapy for Q fever. Some macrolides are 
in pregnancy category B, and could be a safer alternative for treatment in some cases. 
However, it is clear that macrolides are not as effective as doxycycline, and many strains of 
C. burnetii appear to be resistant to erythromycin in vitro [46]. This suggests that macrolides 
should not be a primary choice for Q fever treatment. However, newer macrolides such as 
clarithromycin and azithromycin could be explored further and represent a possible 
alternative therapy, especially during pregnancy.
A common contemporary alternative to doxycycline is co-trimoxazole. This drug is a 
mixture of trimethoprim and sulfamethaxzole at a 1 to 5 ratio. It functions as a folic acid 
antagonist and blocks DNA synthesis to reduce bacterial replication. Co-trimoxazole is the 
recommended treatment for pregnant women as it has activity against C. burnetii, and when 
supplemented with folic acid, has a better safety profile in pregnancy than doxycycline [23]. 
The use of co-trimoxazole for Q fever during pregnancy is based primarily on a study 
published in 2007 that found benefit with co-trimoxazole therapy for at least 5 weeks during 
pregnancy [49]. Q fever patients that were put on co-trimoxazole long-term during 
pregnancy developed fewer obstetric problems than patients that did not receive this 
treatment. Pregnant patients treated with co-trimoxazole were also less likely to develop a 
chronic Q fever serologic profile [49]. Although other studies have found that the benefit of 
long term treatment during pregnancy may not be as large as that found in the 2007 study 
[41], and questions about the risk of using co-trimoxazole during pregnancy remain, current 
recommendations are for long-term co-trimoxazole treatment for pregnant Q fever patients 
[23,49]. Co-trimoxazole has been used sporadically for chronic Q fever, with variable 
results. Successful clearance of the bacteria has been reported, but also failures. It is 
recommended that pregnant women with a chronic serologic profile be placed on 
doxycycline plus hydroxychloroquine after delivery [23,49].
Expert commentary and five-year view
Doxycycline remains the first choice of treatment for acute Q fever, and doxycycline plus 
hydroxychloroquine is the first choice for chronic Q fever. No alternatives have the efficacy 
of doxycycline, and it has a long track record in successful treatment of C. burnetii 
infections [28]. A problem with the use of doxycycline for acute Q fever is the diagnostic 
delay. Q fever is rarely suspected in acute febrile illnesses, although studies have shown that 
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it may be a fairly common cause of febrile disease [62,63]. If diagnostics are ordered, it 
usually consists of a serologic assay which provides a single titer. The prevalence of Q fever 
antibodies in the general population (3.1% in the US) makes it impossible to distinguish 
between a current infection and past infection based on one titer result [62]. In addition, 
titers may not be present until 7-10 days after symptom onset. For these reasons, a 
confirmed diagnosis usually depends on comparison between acute and convalescent serum 
samples, with a four-fold rise in IgG against Phase 2 C. burnetii confirming a diagnosis. 
This is of course not useful for a treatment decision, as the convalescent sample will be 
taken in most cases after symptoms have resolved and treatment is not recommended for 
asymptomatic patients. Thus, the diagnostic delay is an obstacle to timely treatment with 
doxycycline. The use of PCR can provide a much more timely diagnosis. C. burnetii DNA 
can be detected both in whole blood and serum in the time before IgG antibodies are present 
in the blood. PCR can therefore provide a positive diagnosis while patients are symptomatic 
and guide treatment decisions. In the recent Q fever epidemic in the Netherlands, PCR was 
considered an essential aspect of the diagnostic protocol [21]. Increased use of PCR for Q 
fever diagnostics could make administration of doxycycline for symptomatic patients more 
realistic.
For many years, chronic Q fever was a very difficult disease to treat, and there were many 
examples of relapse and treatment failures [10,28]. For these reasons various alternative 
therapies have been explored. The advent of the combination of doxycycline plus 
hydroxychloroquine as a treatment for Q fever endocarditis in the 1990’s has been very 
beneficial to patients as this has reduced relapses and the need for valve replacements [33]. 
However, this treatment still requires 18 months of antibiotic therapy, and some patients 
cannot tolerate doxycycline. Hydroxychloroquine can also cause ocular toxicity and may not 
be tolerated due to an impaired visual field. Although not common, isolates resistant to 
doxycycline have been reported [46,47]. It is therefore worthwhile to search for alternative 
treatments for Q fever endocarditis. Quinolones, rifampin, co-trimoxazole, and telithromycin 
have all been used on Q fever endocarditis patients [28], but these strategies have all been 
replaced by the doxycycline/hydroxychloroquine protocol [33]. A suitable alternative will 
need to have bactericidal activity and be tolerated for fairly long-term use.
An open question for Q fever treatment is the value of treating acute fever in preventing the 
later development of Q fever endocarditis. Rapid diagnosis and treatment of acute Q fever 
may not only be important for the relief of symptoms of the acute disease but could also 
have a role in preventing evolution of chronic disease. There could also be a benefit for high 
risk patients in longer term treatment after the normal two-week course of doxycycline. A 
recent report has evaluated the benefit of screening acute Q fever patients for valvulopathies 
and treating all patients with significant valvulopathies with doxycycline/
hydroxychloroquine for 12 months [64]. This study found 31/72 acute Q fever patients had a 
significant valvulopathy. Eighteen of the 31 patients with acute Q fever and valvulopathy 
received doxycycline/hydroxychloroquine for 1 year and did not develop endocarditis 
during the follow-up period (1-4 years). The 13 patients that had acute Q fever and 
valvulopathy but did not receive prophylactic antibiotic treatment all developed endocarditis 
within one year. This study emphasizes the risk of endocarditis for acute Q fever patients 
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with valvulopathy [14,64], and shows that it is possible to prevent endocarditis with 
doxycycline/hydroxychloroquine therapy. However, in other contexts, the benefit of 
screening every acute fever patient for valvulopathy may not be as significant [65]. Other 
patient groups may have lower incidence of valvulopathy and certain strains of C. burnetii 
may have more or less propensity for endocarditis [14].
The need for long-term treatment for Q fever during pregnancy is based on a limited number 
of patients. The rationale comes primarily from a study of 53 patients in France that had 
high rates of obstetric complications without therapy, but a very significant reduction with 
long-term (5 weeks or more) co-trimoxazole treatment [49]. Other studies have also found 
negative implications of Q fever during pregnancy [15-18]. However, a recent study from 
Germany of 11 women with Q fever during pregnancy found none with obstetric 
complications related to the infection, even though only 3 received long-term co-
trimoxazole [41]. In the Netherlands, a serosurvey of pregnant women in a region that had 
high incidence of Q fever during 2007-2008 found 37 women with both IgM and IgG 
antibodies against Phase 2 C. burnetii, suggesting a recent infection [42]. The incidence of 
fetal complications was the same in this seropositive group as that found in seronegative 
mothers from the same region, suggesting that C. burnetii infection in these cases did not 
lead to adverse pregnancy outcomes [42]. Reasons for differences in the incidence of 
adverse pregnancy outcomes related to Q fever are not currently known. One possibility is 
that C. burnetii strain differences can impact the effect on pregnancy [50]. Because long-
term treatment with antibiotics poses some risk to the fetus, it will be important to better 
understand the risks of C. burnetii infection for the fetus so that risk/benefit calculations can 
be weighed more effectively. Evaluation of genotype-specific impact on pregnancy could 
shed light on this matter.
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• Coxiella burnetii infection can result in Q fever, a febrile illness that can include 
myalgia, fatigue, and severe headache.
• Q fever can present in an acute form, which is a disease that can resolve in less 
than 14 days, or a chronic form. The chronic form often presents as endocarditis 
or vascular infection and can be life threatening.
• Acute Q fever is treated with doxycycline and chronic Q fever with doxycycline 
plus hydroxychloroquine.
• Co-trimoxazole is an alternative antimicrobial that is recommended for children 
less than 8 years old and for pregnant women diagnosed with Q fever.
• Alternative antibiotics are needed due to the possibility of bioterrorism, 
doxycycline resistance, risk of current therapies to fetal health, and long course 
of current therapies.
• Quinolones, co-trimoxazole, rifampin, and some macrolides are possible 
alternative drug treatments for Q fever, but none perform as well as 
doxycycline.
• Some benefit may exist in aggressive screening and treatment for pregnant 
women and patients with valvulopathies, but more study is needed.
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